Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 14/20 | 0.51 |
| ▸ | DRD3 | P35462 | 14/20 | 0.51 |
| ▸ | DRD2 | P14416 | 9/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6411603 | 1.00 | HTR2A (0.51) | HTR2ADRD3DRD2HTR1ACHRM1 | |
| SCHEMBL6411080 | 0.94 | CHRM1 (0.49) | HTR2ADRD3DRD2HTR1ACHRM1 | |
| SCHEMBL6411076 | 0.94 | CHRM1 (0.49) | HTR2ADRD3DRD2HTR1ACHRM1 | |
| SCHEMBL6415049 | 0.91 | HTR2A (0.52) | HTR2ADRD3DRD2HTR1ASLC6A4 | |
| SCHEMBL6415055 | 0.91 | HTR2A (0.52) | HTR2ADRD3DRD2HTR1ASLC6A4 | |
| SCHEMBL6415023 | 0.90 | DRD3 (0.59) | HTR2ADRD3DRD2HTR1ASLC6A4 | |
| SCHEMBL6415020 | 0.90 | DRD3 (0.59) | HTR2ADRD3DRD2HTR1ASLC6A4 | |
| SCHEMBL6411066 | 0.90 | DRD3 (0.55) | HTR2ADRD3DRD2HTR1ASLC6A4 | |
| SCHEMBL6411064 | 0.90 | DRD3 (0.55) | HTR2ADRD3DRD2HTR1ASLC6A4 | |
| SCHEMBL6410096 | 0.89 | DRD3 (0.47) | HTR2ADRD3DRD2HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065140-A1 | Serotonine reuptake inhibitor | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1466901-A1 | SEROTONINE REUPTAKE INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065140-A1 | Serotonine reuptake inhibitor | HTR1A, SLC6A4, SLC6A2 | HTR2A 5/4885DRD3 194/4885DRD2 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.